Zydus' Sentynl buys Nulibry rights from BridgeBio

9 March 2022

Sentynl Therapeutics, a wholly-owned subsidiary of Indian pharma company Zydus Lifesciences (NSE: ZYDUSLIFE), has announced a deal with US biopharma company BridgeBio Pharma (Nasdaq: BBIO).

The firms have agreed an asset purchase agreement for the sale of BridgeBio’s Nulibry (fosdenopterin) for injection, a treatment approved by the US Food and Drug Administration to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening pediatric genetic disorder.

Sentynl will acquire global rights and will be responsible for the ongoing development and commercialization of Nulibry in the USA and developing, manufacturing and commercializing it globally.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK